Literature DB >> 3970715

The effects of primaquine stereoisomers and metabolites on drug metabolism in the isolated perfused rat liver and in vitro rat liver microsomes.

G W Mihaly, S A Ward, D D Nicholl, G Edwards, A M Breckenridge.   

Abstract

The effect of the antimalarial drug primaquine, its stereoisomers and its proposed metabolites, on the metabolism of substrates for mixed function oxidase, has been studied in isolated perfused rat livers (IPRL) and/or in vitro microsomal suspension. Following acute administration to an IPRL preparation, racemic primaquine produced a dose related reduction in the hepatic clearance of antipyrine which at the highest dose of primaquine (5.0 mg) represented a decrease to 46% of control values. Antipyrine clearance was reduced to a comparable extent by the (+) and (-) isomers and the racemic mixture (each at a dose of 2.5 mg) with mean reductions of 45, 49 and 47%, respectively. These changes in clearance were reflected by significant increases in half-life relative to control. The apparent volume of distribution of antipyrine was unchanged in all experiments. Racemic primaquine and its (+) and (-) isomers were equipotent in inhibiting aminopyrine N-demethylase activity, producing reductions of 56, 59 and 55%, respectively, relative to control values. These three compounds also produced corresponding reductions of 73, 58 and 73% in ethoxyresorufin O-deethylase activity. The N-acetyl and 5-hydroxy derivative of primaquine produced inhibitory effects comparable to that seen for the parent drug. In contrast the carboxylic acid metabolite of primaquine, 6-desmethylprimaquine and 5-hydroxy-6-desmethyl primaquine did not influence aminopyrine N-demethylase activity. These results indicate that the propensity to inhibit drug metabolism by these primaquine related substances, is influenced by functional group substitution rather than the optical activity of the parent drug.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3970715     DOI: 10.1016/0006-2952(85)90040-1

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  8 in total

1.  Single dose primaquine has no effect on paracetamol clearance.

Authors:  D J Back; J F Tjia
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 2.  Inhibition of drug metabolism by quinolone antibiotics.

Authors:  D J Edwards; S K Bowles; C K Svensson; M J Rybak
Journal:  Clin Pharmacokinet       Date:  1988-09       Impact factor: 6.447

3.  Simultaneous and enantiospecific quantification of primaquine and carboxyprimaquine in human plasma using liquid chromatography-tandem mass spectrometry.

Authors:  Warunee Hanpithakpong; Nicholas P J Day; Nicholas J White; Joel Tarning
Journal:  Malar J       Date:  2022-06-03       Impact factor: 3.469

4.  Pharmacokinetics of mefloquine in combination with sulfadoxine-pyrimethamine and primaquine in male Thai patients with falciparum malaria.

Authors:  J Karbwang; D J Back; D Bunnag; A M Breckenridge
Journal:  Bull World Health Organ       Date:  1990       Impact factor: 9.408

5.  Interactions among primaquine, malaria infection and other antimalarials in Thai subjects.

Authors:  G Edwards; C S McGrath; S A Ward; W Supanaranond; S Pukrittayakamee; T M Davis; N J White
Journal:  Br J Clin Pharmacol       Date:  1993-02       Impact factor: 4.335

6.  Effect of toremifene on antipyrine elimination in the isolated perfused rat liver.

Authors:  L K Webster; A G Ellis; J F Bishop
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

7.  In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines.

Authors:  D J Back; J F Tjia; J Karbwang; J Colbert
Journal:  Br J Clin Pharmacol       Date:  1988-07       Impact factor: 4.335

8.  Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide.

Authors:  D J Back; J Tjia; H Mönig; E E Ohnhaus; B K Park
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.